Effect of Pioglitazone on Glucose and Glycation Level in Type 2 Diabetic Patients

To elucidate the effects of pioglitazone treatment on glucose and glycation level in patients with type 2 diabetes, a total of 8 patients were treated with pioglitazone (30 mg day-1) for 12 weeks. After this period, there was a significant decrease in fasting plasma glucose and glycation level. The fasting plasma glucose was decreased from 195 to 159 mg per dL and glycation level decreased from 0.140 to 0.113 moles of glucose per moles of protein. These results suggest that pioglitazone decreases fasting plasma glucose in type 2 diabetic patients and acts as an inhibitor of glycation in-vivo. © 2010 Friends Science Publishers